Overview
- About 250 participants are being recruited, including patients having ovaries removed for cancer treatment and BRCA carriers opting for risk‑reducing surgery.
- The device being evaluated was developed by biotechnology company Daye and will be used alongside vaginal swabs and surgical tissue sampling.
- Researchers will compare microRNA biomarker patterns across vaginal fluid and tissue to identify signatures linked to early ovarian cancer.
- Investigators say positive results would prompt larger validation trials, describing the potential of a non‑invasive test as a possible game‑changer if proven.
- The trial is led by University Hospital Southampton teams with support from the Southampton Clinical Trials Unit and the University’s Centre for Cancer Immunology, funded by The Eve Appeal, against a backdrop of no UK screening and roughly 7,500–7,600 cases annually.